Puma Biotech (PBYI) Tops Q4 EPS by 31c

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.21, $0.31 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $51 million versus the consensus estimate of $46.85 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Kroger meets earnings expectations, revenue tops estimates
• JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral